Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$2.80 -1.8%	$1.74	$0.73 ▼ $3.90	$177.22M	0.7	417,215 shs	406,858 shs
HEPA Hepion Pharmaceuticals	$0.05 -6.4%	$0.10	$0.04 ▼ $56.00	$528K	1.69	1.31 million shs	167,732 shs
LMNL Liminal BioSciences	$8.50	$8.47	$3.10 ▼ $8.50	$26.35M	1.03	63,470 shs	N/A
LPCN Lipocine	$3.00 -6.3%	$3.30	$2.68 ▼ $7.61	$16.05M	1.3	33,327 shs	36,066 shs
SYBX Synlogic	$1.32 +6.5%	$1.18	$0.90 ▼ $1.88	$15.44M	0.55	18,251 shs	390,420 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	+13.55%	+32.56%	+108.03%	+112.69%	+27.23%
HEPA Hepion Pharmaceuticals	-6.17%	-21.81%	-19.69%	-83.91%	-99.89%
LMNL Liminal BioSciences	0.00%	0.00%	0.00%	0.00%	0.00%
LPCN Lipocine	-2.14%	+2.89%	+2.56%	+4.92%	-58.39%
SYBX Synlogic	0.00%	+2.94%	-0.81%	+17.22%	-17.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GALT Galectin Therapeutics	2.2706 of 5 stars	3.5	2.0	0.0	0.0	3.3	1.7	0.0
HEPA Hepion Pharmaceuticals	0.2633 of 5 stars	0.0	3.0	0.0	0.0	1.1	0.0	0.6
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	3.0293 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.0	0.6
SYBX Synlogic	1.1632 of 5 stars	0.0	3.0	0.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GALT Galectin Therapeutics	3.00	Buy	$6.00	114.29% Upside
HEPA Hepion Pharmaceuticals	0.00	N/A	N/A	N/A
LMNL Liminal BioSciences	0.00	N/A	N/A	N/A
LPCN Lipocine	3.00	Buy	$9.00	200.00% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SYBX, LPCN, GALT, LMNL, and HEPA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.29 per share	N/A
LMNL Liminal BioSciences	$310K	85.00	N/A	N/A	$8.97 per share	0.95
LPCN Lipocine	$3.67M	4.37	N/A	N/A	$3.93 per share	0.76
SYBX Synlogic	$10K	1,544.40	N/A	N/A	$1.09 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	8/12/2025 (Estimated)
HEPA Hepion Pharmaceuticals	-$48.93M	-$219.00	N/A	∞	N/A	N/A	-812.56%	-207.31%	8/11/2025 (Estimated)
LMNL Liminal BioSciences	$380K	$0.29	29.31	∞	N/A	248.35%	-88.44%	-64.15%	N/A
LPCN Lipocine	$10K	-$1.02	N/A	∞	N/A	N/A	-26.68%	-24.77%	8/6/2025 (Estimated)
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	10.91%	7.47%	8/6/2025 (Estimated)

Latest SYBX, LPCN, GALT, LMNL, and HEPA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	GALT Galectin Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/8/2025	Q4 2024	LPCN Lipocine	-$0.35	-$0.35	N/A	-$0.35	$0.35 million	$0.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LMNL Liminal BioSciences	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GALT Galectin Therapeutics	N/A	0.08	0.08
HEPA Hepion Pharmaceuticals	N/A	1.30	1.30
LMNL Liminal BioSciences	0.02	2.78	2.78
LPCN Lipocine	N/A	15.64	15.64
SYBX Synlogic	N/A	3.68	3.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GALT Galectin Therapeutics	11.68%
HEPA Hepion Pharmaceuticals	17.24%
LMNL Liminal BioSciences	0.66%
LPCN Lipocine	9.11%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
GALT Galectin Therapeutics	50.10%
HEPA Hepion Pharmaceuticals	0.06%
LMNL Liminal BioSciences	2.20%
LPCN Lipocine	6.35%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable
HEPA Hepion Pharmaceuticals	20	10.93 million	6.63 million	No Data
LMNL Liminal BioSciences	251	3.10 million	3.04 million	Not Optionable
LPCN Lipocine	10	5.35 million	5.01 million	No Data
SYBX Synlogic	80	11.70 million	11.34 million	Optionable

SYBX, LPCN, GALT, LMNL, and HEPA Headlines

Recent News About These Companies

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX, LPCN, GALT, LMNL, and HEPA Company Descriptions

Galectin Therapeutics NASDAQ:GALT

$2.80 -0.05 (-1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$2.80 +0.01 (+0.18%)

As of 06:22 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Hepion Pharmaceuticals NASDAQ:HEPA

$0.05 0.00 (-6.40%)

As of 03:53 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Liminal BioSciences NASDAQ:LMNL

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Lipocine NASDAQ:LPCN

$3.00 -0.20 (-6.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.06 +0.06 (+1.83%)

As of 06:57 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Synlogic NASDAQ:SYBX

$1.32 +0.08 (+6.45%)

Closing price 03:59 PM Eastern

Extended Trading

$1.31 -0.01 (-0.68%)

As of 05:33 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time